Ob/Gyn Medical News about postmenopausal women

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Hormone therapy and risk of venous thromboembolism among postmenopausal women
Climacteric, 09/16/09

Canonico M et al. – Recent studies have shown that transdermal estrogens might be safe with respect to thrombotic risk. The difference in thrombotic risk between oral and transdermal estrogens may be partially explained by changes in hemostasis. Few data are currently available regarding the impact of progestogens on venous thromboembolism risk, but norpregnane derivatives might be thrombogenic. Individual assessment of the benefit–risk ratio is needed before initiating treatment and oral estrogens should be avoided among women at high risk for venous thromboembolism.

<< Previous
Hypoxia inducible factors regulate pluripotency and proliferation...

Next >>
Metastasis of Breast Cancer to a Lumbar Spinal Nerve Root...